1,185 patents currently held
1,531 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
52 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Of the 1,531 now held by other companies, 1,018 name Alcon Inc. as their current owner, and 513 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
257
Ending by 2030
Nov 2026
Next term end
750
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2035 · High confidence
Also notable
Ends Dec 2034 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Feb 2034 · High confidence
Also notable
Ends Jan 2035 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Mar 2031 · High confidence
Also notable
Ends Jan 2035 · High confidence
Antibody Molecules to PD-1 and Uses Thereof
US 9,683,048
The most cited patent in this portfolio, cited by 288 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2035.
Lipids and Lipid Compositions for the Delivery of Active Agents
US 10,906,867
Cited by 50 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2034.
Compositions and Methods for Increasing Muscle Growth
US 8,388,968
Cited by 147 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Treatment of Cancer Using Humanized Anti-Egfrviii Chimeric Antigen Receptor
US 9,394,368
Cited by 222 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Antibody Molecules to TIM-3 and Uses Thereof
US 9,605,070
Cited by 172 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
FIBROBLAST GROWTH FACTOR-21-Fc FUSION PROTEINS
US 9,006,400
Cited by 62 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Pyridine and Pyrazine Derivative for the Treatment of CF
US 8,247,436
Cited by 74 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
N-Azaspirocycloalkane Substituted N-Heteroaryl Compounds and Compositions for Inhibiting the Activity of SHP2
US 10,077,276
Cited by 38 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Oct 2027 · High confidence
Cited by 636 later US patents, top 1% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Alcon Inc.
Also notable
Ends Jun 2031 · High confidence
Cited by 42 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
conveyed to GlaxoSmithKline Biologicals S.A.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Crystalline Forms of 5-Bromo-2,6-DI(1H-PYRAZOL-1-YL)PYRIMIDIN-4-Amine and New Salts (US 11,654,144) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 10 fees due Dec 2 to 30, 2026 · next Dec 2
- 15 fees due Jan 2 to 30, 2027 · next Jan 2
- 17 fees due Feb 6 to 28, 2027 · next Feb 6
- 21 fees due Mar 3 to 29, 2027 · next Mar 3
- 23 fees due Apr 1 to 30, 2027 · next Apr 1
- 17 fees due May 3 to 28, 2027 · next May 3
- 16 fees due Jun 3 to 30, 2027 · next Jun 3
- 24 fees due Jul 2 to 28, 2027 · next Jul 2
- 15 fees due Aug 4 to 27, 2027 · next Aug 4
- 31 fees due Sep 1 to 30, 2027 · next Sep 1
- 21 fees due Oct 2 to 30, 2027 · next Oct 2
- 14 fees due Nov 5 to 19, 2027 · next Nov 5
Recent changes
- Nov 6Assignment recorded on 1 record: Novartis Pharmaceutical Manufacturing GmbH to Novartis AG Recorded Nov 6, 2026, executed Jul 3, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76661, frame 316.
- Nov 6Assignment recorded on 1 record: Novartis Pharma AG to Novartis AG Recorded Nov 6, 2026, executed Jun 24, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76662, frame 95.
- 19 of the patents on this record were granted since Aug 23, 2026
- 54 terms have ended since Aug 23, 2026
- Nov 21 US 7,855,782 Lens Inspection System Using Phase Contrast Imaging · term ended
- Nov 20 US 8,014,052 System and Method for Illumination Attenuation · term ended
- Nov 14 US 7,758,546 Variable Flow Device · term ended
- Nov 8 US 9,388,134 Compounds Containing S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE and (2R,4S)-5-Biphenyl-4-YL-4-(3-Carboxy-PROPIONYLAMINO)-2-Methyl-PENTANOIC Acid Ethyl Ester Moieties and Cations · term ended
- Nov 8 US 11,642,329 Amorphous Solid Form of Compounds Containing S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE and (2R,4S)-5-Biphenyl-4-YL-4-(3-Carboxy-PROPIONYLAMINO)-2-Methyl-PENTANOIC Acid Ethyl Ester Moieties and Sodium Cations · term ended
- Nov 8 US 11,096,918 Amorphous Solid Form of Compounds Containing S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE and (2R,4S)-5-Biphenyl-4-YL-4-(3-Carboxy-PROPIONYLAMINO)-2-Methyl-PENTANOIC Acid Ethyl Ester Moieties and Sodium Cations · term ended
- Nov 6 US 9,649,377 Methods of Using IL-1beta Compounds to treat Familial Mediterranean Fever (FMF) · term ended
- Nov 6 US 10,842,867 Adjuvanted Vaccines with Non-Virion Antigens Prepared from Influenza Viruses Grown in Cell Culture · term ended
- Nov 5 US 7,667,039 1,3-Dihydro-IMIDAZO [4,5-c] QUINOLIN-2-ONES as Lipid Kinase Inhibitors · term ended
- Nov 3 US 7,573,974 Device and Method for Non-Contact Scanning of Contact Lens and Contact Lens Mold Geometry · term ended
- Oct 30 US 9,326,826 Gas Pressure Monitor for Pneumatic Surgical Machine · term ended
- Oct 30 US 10,112,931 3-Pyrimidin-4-YL-OXAZOLIDIN-2-ONES as Inhibitors of Mutant Idh · lapsed on the fee record
- Oct 28 US 8,871,754 Compounds and Compositions for the Treatment of Parasitic Diseases · lapsed on the fee record
- Oct 25 US 7,759,308 Microparticles Comprising Somatostatin Analogues · term ended
- Oct 25 US 7,678,383 Aminoacetonitrile Compounds for Controlling Endoparasites · term ended
What they patent
The largest of its 750 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,017,621 | Inhibitors of the Mutant Form of Kit In force · High confidence | In force | High confidence | |
| US 7,713,976 | Organic Compounds held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 7,713,977 | Organic Compounds held by Novartis AG and Novartis Pharma GmbH In force · High confidence | In force | High confidence | |
| US 8,906,936 | Pharmaceutical Combination Comprising Co-Administration of Taxane and N-(1-Cyclohexyl-2-{2-[4-(4-Fluoro-BENZOYL)-THIAZOL-2-YL]-PYRROLIDIN-1-YL}-2-OXO-ETHYL)-2-Methylamino-PROPIONAMIDE or Pharmaceutically Acceptable Salt(S) Thereof In force · Medium confidence | In force | Medium confidence | |
| US D673,264 | Injector In force · Medium confidence | In force | Medium confidence | |
| US 7,557,135 | Inhibitors of Cytosolic Phospholipase A2 In force · High confidence | In force | High confidence | |
| US 7,709,657 | Process for the Synthesis of Organic Compounds In force · High confidence | In force | High confidence | |
| US 7,691,180 | Mixtures of Ionic Liquids with Lewis Acids In force · High confidence | In force | High confidence | |
| US D677,785 | Medicine Injector In force · High confidence | In force | High confidence | |
| US 7,956,177 | Dsrna Compositions and Methods for Treating HPV Infection In force · High confidence | In force | High confidence |
Also on record, not counted in the 1,185: 1,531 patents in force now held by others · 1,950 patents ended · 437 applications pending · 2,433 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.